Summary
Emerging biotech companies are a significant and burgeoning sector of the pharmaceutical development market. These companies may require unique and specialized expertise to guide them through asset development. There are a multitude of considerations when evaluating an asset for development, including the vision for the asset, development and continuum capabilities, and global versus local development.
Download our latest whitepaper to learn:
- How to navigate the complexities of asset development
- Overall considerations emerging biotech companies can be discussing with development partners
- What makes a successful partner who can assist a small biotech company with necessary development strategies
This is the first in a series of white papers that will help outline considerations for asset development. Lead the pack in all steps of the development process with this guide.
Register to download
Biotech and Early Engagement Considerations: What Companies Must Consider When Developing an Asset
You may also be interested in:
Blog
5 Questions Small Biotech Should Ask Their Rare Disease Development Partner
Rare disease is a complicated but rewarding space for drug developers of all sizes. Most rare diseases have no approved treatment options, making…
Case Study
Small Biotechnology Partnerships – A Success Story
PRA has experience partnering with small biotech firms, and we understand that they require a different approach than larger pharmaceutical…
Blog
Much More Than a Single Clinical Trial
Delivering drugs to the patients who need them can be an increasingly complex, time-consuming, and costly undertaking, particularly for smaller…